Tema Etfs LLC Buys Shares of 115,431 Immunome, Inc. $IMNM

Tema Etfs LLC bought a new stake in Immunome, Inc. (NASDAQ:IMNM) during the second quarter, HoldingsChannel.com reports. The institutional investor bought 115,431 shares of the company’s stock, valued at approximately $1,074,000.

Several other hedge funds have also recently modified their holdings of the stock. T. Rowe Price Investment Management Inc. grew its position in Immunome by 37.4% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 7,554,594 shares of the company’s stock valued at $50,843,000 after buying an additional 2,054,640 shares during the last quarter. Redmile Group LLC raised its position in Immunome by 11.0% during the 1st quarter. Redmile Group LLC now owns 5,361,187 shares of the company’s stock worth $36,081,000 after buying an additional 533,161 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Immunome by 43.4% in the 1st quarter. Vanguard Group Inc. now owns 4,307,191 shares of the company’s stock worth $28,987,000 after acquiring an additional 1,303,753 shares during the period. EcoR1 Capital LLC lifted its stake in shares of Immunome by 5.2% in the 1st quarter. EcoR1 Capital LLC now owns 4,079,415 shares of the company’s stock worth $27,454,000 after acquiring an additional 200,000 shares during the period. Finally, Primecap Management Co. CA boosted its holdings in shares of Immunome by 1,115.7% in the first quarter. Primecap Management Co. CA now owns 3,413,700 shares of the company’s stock valued at $22,974,000 after acquiring an additional 3,132,900 shares in the last quarter. 44.58% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently issued reports on IMNM. Evercore ISI assumed coverage on shares of Immunome in a report on Friday, August 22nd. They set an “outperform” rating and a $18.00 price target for the company. Wedbush reaffirmed an “outperform” rating and issued a $21.00 price objective on shares of Immunome in a report on Friday, November 7th. Truist Financial initiated coverage on Immunome in a research note on Monday. They set a “buy” rating and a $36.00 target price for the company. JPMorgan Chase & Co. reduced their price target on Immunome from $23.00 to $22.00 and set an “overweight” rating for the company in a report on Thursday, August 7th. Finally, The Goldman Sachs Group began coverage on Immunome in a research note on Monday, September 22nd. They issued a “buy” rating and a $26.00 price target on the stock. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Immunome presently has an average rating of “Moderate Buy” and an average price target of $25.00.

Immunome Price Performance

Shares of Immunome stock opened at $20.09 on Friday. Immunome, Inc. has a 1 year low of $5.15 and a 1 year high of $20.40. The business has a 50 day moving average price of $15.98 and a 200 day moving average price of $11.77. The company has a market capitalization of $1.84 billion, a P/E ratio of -6.81 and a beta of 2.17.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. As a group, research analysts expect that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.